Rhamnan sulphate composition for treatment of endothelial dysfunction
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 28, 2004
Grant Date -
Jun 17, 2004
app pub date -
Dec 16, 2002
filing date -
Dec 16, 2002
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The invention described is a method and composition for inducing cell surface anti-thrombotic activity in endothelial cells comprising administering to a patient a therapeutically-effective amount of Rhamnan Sulphate. The dose of Rhamnan Sulphate is equivalent to between approximately 8,000 IU and 12,000 IU of heparin activity daily on variable schedule or optionally at single dosage of 7.5 mg/kg, that is repeated on a daily basis as needed, to lower the incidence of thrombus formation or to lower the incidence of hard clot formation.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully